Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
Journal of Drugs in Dermatology · 2023
DOI: 10.36849/jdd.7592 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Drugs in Dermatology, 2023. Verfasst von Lawrence F Eichenfield und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Acne Vulgaris. Die Arbeit wurde bisher 14-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Eichenfield, L. F., Hebert, A. A., Gold, L. S., Cartwright, M., Moro, L., Han, J., Squittieri, N., & Mazzetti, A. (2023). Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7592
Vancouver
Eichenfield LF, Hebert AA, Gold LS, Cartwright M, Moro L, Han J, et al. Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7592
BibTeX
@article{Eichenfield2023,
author = {Eichenfield, Lawrence F and Hebert, Adelaide A and Gold, Linda Stein and Cartwright, Martina and Moro, Luigi and Han, Jenny and Squittieri, Nicholas and Mazzetti, Alessandro},
title = {Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris},
journal = {Journal of Drugs in Dermatology},
year = {2023},
doi = {10.36849/jdd.7592}
}
EUVIMED